Pazopanib for the treatment of renal cell carcinoma

被引：16
作者：
Welsh, Sarah J. [1 ]
Fife, Kate [1 ]
机构：
[1] Cambridge Univ Hosp NHS Fdn Trust, Cambridge CB2 0QQ, England
来源：
FUTURE ONCOLOGY | 2015年 / 11卷 / 08期
关键词：
antiangiogenic; kidney; pazopanib; renal cancer; treatment; tyrosine kinase inhibitor; DOUBLE-BLIND; PHASE-III; TARGETED THERAPIES; SUNITINIB; SAFETY; EFFICACY; TRIAL;
D O I：
10.2217/fon.14.274
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The incidence and mortality from renal cell cancer (RCC) is increasing. RCC tumors are particularly vascular in nature as a result of disruption of the VHL gene and/or its upstream pathway leading to upregulation of the hypoxia-inducible factor transcription factor. The hypoxia-inducible factor pathway drives angiogenesis by upregulating VEGF and bFGF, amongst other proangiogenic downstream target genes. Therapies which target angiogenesis have been successful in treating metastatic RCC (mRCC) and the receptor tyrosine kinase inhibitor, pazopanib, is licensed for first line treatment of mRCC. This review details the past, current and future roles of pazopanib in the treatment of mRCC.
引用
收藏
页码：1169 / 1179
页数：11
相关论文
共 38 条
  • [1] A phase II study of pazopanib (P) in patients (Pts) with localized renal cell carcinoma (RCC) to enable partial nephrectomy (PN).
    Alvarez, Adriana L.
    Plimack, Elizabeth R.
    Dreicer, Robert
    Gilligan, Timothy D.
    Garcia, Jorge A.
    Elson, Paul
    Campbell, Steven C.
    Krishnamurthi, Venkatesh
    Kaouk, Jihad
    Fergany, Amr Farouk
    Uzzo, Robert G.
    Stephenson, Andrew J.
    Wood, Laura S.
    Chen, David Y. T.
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] [Anonymous], J CLIN ONCOL S
  • [3] Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
    Bettegowda, Chetan
    Sausen, Mark
    Leary, Rebecca J.
    Kinde, Isaac
    Wang, Yuxuan
    Agrawal, Nishant
    Bartlett, Bjarne R.
    Wang, Hao
    Luber, Brandon
    Alani, Rhoda M.
    Antonarakis, Emmanuel S.
    Azad, Nilofer S.
    Bardelli, Alberto
    Brem, Henry
    Cameron, John L.
    Lee, Clarence C.
    Fecher, Leslie A.
    Gallia, Gary L.
    Gibbs, Peter
    Le, Dung
    Giuntoli, Robert L.
    Goggins, Michael
    Hogarty, Michael D.
    Holdhoff, Matthias
    Hong, Seung-Mo
    Jiao, Yuchen
    Juhl, Hartmut H.
    Kim, Jenny J.
    Siravegna, Giulia
    Laheru, Daniel A.
    Lauricella, Calogero
    Lim, Michael
    Lipson, Evan J.
    Marie, Suely Kazue Nagahashi
    Netto, George J.
    Oliner, Kelly S.
    Olivi, Alessandro
    Olsson, Louise
    Riggins, Gregory J.
    Sartore-Bianchi, Andrea
    Schmidt, Kerstin
    Shih, Ie-Ming
    Oba-Shinjo, Sueli Mieko
    Siena, Salvatore
    Theodorescu, Dan
    Tie, Jeanne
    Harkins, Timothy T.
    Veronese, Silvio
    Wang, Tian-Li
    Weingart, Jon D.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)
  • [4] Assessing the Response to Targeted Therapies in Renal Cell Carcinoma: Technical Insights and Practical Considerations
    Bex, Axel
    Fournier, Laure
    Lassau, Nathalie
    Mulders, Peter
    Nathan, Paul
    Oyen, Wim J. G.
    Powles, Thomas
    [J]. EUROPEAN UROLOGY, 2014, 65 (04) : 766 - 777
  • [5] Boleti E, 2012, J CLIN ONCOL S5, V30
  • [6] Pazopanib versus Sunitinib in Renal Cancer
    Ramaekers, Ryan
    Tharnish, Mark
    Copur, M. Sitki
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (20)
  • [7] VHL Gene Mutations in Renal Cell Carcinoma: Role as a Biomarker of Disease Outcome and Drug Efficacy
    Cowey, C. Lance
    Rathmell, W. Kimryn
    [J]. CURRENT ONCOLOGY REPORTS, 2009, 11 (02) : 94 - 101
  • [8] Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
    de Jonge, Maja J. A.
    Hamberg, Paul
    Verweij, Jaap
    Savage, Shawna
    Suttle, A. Benjamin
    Hodge, Jeffrey
    Arumugham, Thangam
    Pandite, Lini N.
    Hurwitz, Herbert I.
    [J]. INVESTIGATIONAL NEW DRUGS, 2013, 31 (03) : 751 - 759
  • [9] Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy
    Dranitsaris, George
    Schmitz, Susanne
    Broom, Reuben J.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (11) : 1917 - 1926
  • [10] VEGF signaling inside vascular endothelial cells and beyond
    Eichmann, Anne
    Simons, Michael
    [J]. CURRENT OPINION IN CELL BIOLOGY, 2012, 24 (02) : 188 - 193
1234